Skip to main content
Erschienen in: Reactions Weekly 1/2018

01.12.2018 | Case report

Crizotinib

Hepatotoxicity and drug resisitance: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Tsakiri K, et al. Crizotinib failure in a TPM4- ALK-rearranged inflammatory myofibroblastic tumor with an emerging ALK kinase domain mutation. JCO Precision Oncology 2017: 1-7, No. 1, 2017. Available from: URL: http://doi.org/10.1200/PO.17.00015 - Greece Tsakiri K, et al. Crizotinib failure in a TPM4- ALK-rearranged inflammatory myofibroblastic tumor with an emerging ALK kinase domain mutation. JCO Precision Oncology 2017: 1-7, No. 1, 2017. Available from: URL: http://​doi.​org/​10.​1200/​PO.​17.​00015 - Greece
Metadaten
Titel
Crizotinib
Hepatotoxicity and drug resisitance: case report
Publikationsdatum
01.12.2018
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2018
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-018-55005-x

Weitere Artikel der Ausgabe 1/2018

Reactions Weekly 1/2018 Zur Ausgabe

Case report

Heparin

Case report

Ofloxacin

Case report

Multiple drugs